Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Planchard

Showing results (1-10 of 243) with videos related to

Pageof 25
Sort By:
Targeted Oncology|February 2, 2013
Identification of driver mutations in lung cancer: first step in personalized cancerDavid Planchard
Expert Review of Anticancer Therapy|September 16, 2011
Bevacizumab in non-small-cell lung cancer: a reviewDavid Planchard
Cancer Research and Treatment|November 28, 2024
The Era of Antibody Drug Conjugates in Lung Cancer: Trick or Threat?Mariona Riudavets, David Planchard
Expert Opinion on Drug Safety|January 4, 2021
Safety of current immune checkpoint inhibitors in non-small cell lung cancerPamela Abdayem, David Planchard
Expert Review of Respiratory Medicine|June 30, 2018
Durvalumab for the treatment of non-small cell lung cancerLaura Mezquita, David Planchard
Future Oncology (London, England)|February 20, 2016
Treatment modalities for advanced ALK-rearranged non-small-cell lung cancerIvana Sullivan, David Planchard
Expert Opinion on Pharmacotherapy|December 21, 2022
An update on lorlatinib: a novel first line treatment for <i>ALK</i>-positive advanced lung cancerMariona Riudavets, David Planchard
Frontiers in Medicine|February 3, 2017
Next-Generation <i>EGFR</i> Tyrosine Kinase Inhibitors for Treating <i>EGFR</i>-Mutant Lung Cancer beyond First LineIvana Sullivan, David Planchard
European Respiratory Review : an Official Journal of the European Respiratory Society|July 22, 2021
Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancerPamela Abdayem, David Planchard
Future Oncology (London, England)|November 16, 2017
Durvalumab in non-small-cell lung cancer patients: current developmentsLaura Mezquita, David Planchard
Pageof 25

Showing results (1-10 of 243) with videos related to

Sort By:
Pageof 25
Targeted Oncology|February 2, 2013
Identification of driver mutations in lung cancer: first step in personalized cancerDavid Planchard
Expert Review of Anticancer Therapy|September 16, 2011
Bevacizumab in non-small-cell lung cancer: a reviewDavid Planchard
Cancer Research and Treatment|November 28, 2024
The Era of Antibody Drug Conjugates in Lung Cancer: Trick or Threat?Mariona Riudavets, David Planchard
Expert Opinion on Drug Safety|January 4, 2021
Safety of current immune checkpoint inhibitors in non-small cell lung cancerPamela Abdayem, David Planchard
Expert Review of Respiratory Medicine|June 30, 2018
Durvalumab for the treatment of non-small cell lung cancerLaura Mezquita, David Planchard
Future Oncology (London, England)|February 20, 2016
Treatment modalities for advanced ALK-rearranged non-small-cell lung cancerIvana Sullivan, David Planchard
Expert Opinion on Pharmacotherapy|December 21, 2022
An update on lorlatinib: a novel first line treatment for <i>ALK</i>-positive advanced lung cancerMariona Riudavets, David Planchard
Frontiers in Medicine|February 3, 2017
Next-Generation <i>EGFR</i> Tyrosine Kinase Inhibitors for Treating <i>EGFR</i>-Mutant Lung Cancer beyond First LineIvana Sullivan, David Planchard
European Respiratory Review : an Official Journal of the European Respiratory Society|July 22, 2021
Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancerPamela Abdayem, David Planchard
Future Oncology (London, England)|November 16, 2017
Durvalumab in non-small-cell lung cancer patients: current developmentsLaura Mezquita, David Planchard
Pageof 25